Clinical Trial

Study to Evaluate the Efficacy of Axicabtagene Ciloleucel in Patients With Late Relapse of Diffuse Large B-Cell Lymphoma

Name: Study to Evaluate the Efficacy of Axicabtagene Ciloleucel in Patients With Late Relapse of Diffuse Large B-Cell Lymphoma — clinical trial record (NCT07254754)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: LATE-R-GEL-23

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

Single-arm, open-label, multicenter, phase II trial aiming to include approximately 45 patients over 24 months. Patients will receive axicabtagene ciloleucel infusion and will be followed up to 5 years. The total duration of the study is therefore of 7 years.

Trial Details

NCT Number	NCT07254754
Lead Sponsor	Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea Collaborators: Kite, A Gilead Company, Evidenze CRO
Conditions	DIFFUSE LARGE B-CELL LYMPHOMA
Enrollment	45 participants
Start Date	2024-11-20
Primary Completion	2027-01-31 (estimated)
Study Completion	2031-12-31 (estimated)
Updated on ClinicalTrials.gov	2025-11-28